Title:Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review
VOLUME: 18 ISSUE: 7
Author(s):Manvendra Kumar, Ramit Singla, Jyoti Dandriyal and Vikas Jaitak*
Affiliation:Centre for Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151 001, Centre for Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151 001, Centre for Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151 001, Centre for Pharmaceutical Sciences and Natural Products, School of Basic and Applied Sciences, Central University of Punjab, Bathinda, 151 001
Keywords:Lung cancer, MDR, coumarin, NSCLC, SCLC, multidrug resistance.
Abstract:Background: The prevalence of lung cancer is 14% among the newly diagnosed cancer cases worldwide.
Currently, the number of drugs that are in clinical practice is having a high prevalence of side effect and
multidrug resistance. Researchers have made an attempt to expand a suitable anticancer drug that has no MDR
and side effect.
Objective: Extensive exploration of Coumarin derivatives as a potent inhibitor of variety of proteins including
EGFR, tyrosine kinase, ERK1/2, PI3K, HSP 90, Bax, STAT proteins, NF-κB and telomerase which have been
associated with lung cancer.
Method: The recent literature was surveyed utilizing the online resources and databases including scifinder,
pubchem, EMBL, scopus and google scholar.
Results: Upon analyzing the structure-activity relationship, it was found that N-aryl carboxamide, phenyl substitution
at the C-3 position and 1,2,3- triazolyl, trihydroxystilbene, amino substitution at the C-4 position of the
coumarin nucleus were the most effective in targeting lung cancer.
Conclusion: This review is a collaborative and extensive compilation of synthetic strategies, mechanism of
action, and the structure-activity relationship thereof for the management of lung carcinoma.
